MedPath

Ocunexus Therapeutics, Inc.

🇺🇸United States
Ownership
Holding
Employees
-
Market Cap
-
Website
http://www.ocunexus.com

Clinical Trials

7

Active:0
Completed:5

Trial Phases

2 Phases

Phase 1:3
Phase 2:4

Drug Approvals

0

Drug Approvals

No drug approvals found

This company may not have drug approvals in our database

Clinical Trials

Distribution across different clinical trial phases (7 trials with phase data)• Click on a phase to view related trials

Phase 2
4 (57.1%)
Phase 1
3 (42.9%)

A Study to Investigate the Safety and Clinical Effect of Nexagon® as a Topical Treatment for Subjects With a Diabetic Foot Ulcer (DUNE)

First Posted Date
2011-12-13
Last Posted Date
2014-05-01
Lead Sponsor
OcuNexus Therapeutics, Inc.
Target Recruit Count
168
Registration Number
NCT01490879
Locations
🇺🇸

Associated Foot and Ankle Specialists, LLC, Phoenix, Arizona, United States

🇺🇸

University of Arizona Medical Center, Tucson, Arizona, United States

🇺🇸

Center For Clinical Research Inc., Castro Valley, California, United States

and more 22 locations

A Study to Investigate the Efficacy, Safety and Tolerability of Nexagon® as a Topical Treatment for Subjects With Venous Leg Ulcers

Phase 2
Completed
Conditions
Venous Leg Ulcers
Interventions
First Posted Date
2010-09-13
Last Posted Date
2014-05-01
Lead Sponsor
OcuNexus Therapeutics, Inc.
Target Recruit Count
300
Registration Number
NCT01199588
Locations
🇺🇸

Associated Foot and Ankle Specialists, LLC, Phoenix, Arizona, United States

🇺🇸

Aung Foot Health Clinics, Tucson, Arizona, United States

🇺🇸

Southern Arizona Limb Salvage Alliance, Tucson, Arizona, United States

and more 30 locations

A Study to Investigate the Safety and Clinical Effect of Nexagon® to Treat Persistent Epithelial Defects

Phase 2
Withdrawn
Conditions
Persistent Epithelial Defect
First Posted Date
2009-01-13
Last Posted Date
2010-02-26
Lead Sponsor
OcuNexus Therapeutics, Inc.
Target Recruit Count
90
Registration Number
NCT00821561

The ASCEND Study: A Study to Investigate the Safety and Clinical Effect of Nexagon to Treat Slow Healing Diabetic Foot Ulcers

Phase 1
Terminated
Conditions
Diabetic Foot Ulcer
First Posted Date
2009-01-12
Last Posted Date
2010-08-31
Lead Sponsor
OcuNexus Therapeutics, Inc.
Target Recruit Count
24
Registration Number
NCT00820703
Locations
🇳🇿

Middlemore Hospital, Auckland, New Zealand

A Trial to Assess the Safety and Activity of Nexagon® for the Treatment of Venous Leg Ulcers (The NOVEL Study)

Phase 2
Completed
Conditions
Venous Ulcer
First Posted Date
2009-01-12
Last Posted Date
2012-09-18
Lead Sponsor
OcuNexus Therapeutics, Inc.
Target Recruit Count
98
Registration Number
NCT00820196
Locations
🇺🇸

Centre for Clinical Research, San Francisco, California, United States

🇺🇸

Pacific Wound Center, Stockton, California, United States

🇺🇸

Penn North Centers for Advanced Wound Care, Erie, Pennsylvania, United States

and more 7 locations
  • Prev
  • 1
  • 2
  • Next

News

No news found

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.